Retrophin and the U.S. subsidiary of Britain’s Horizon Pharma will each donate $3 million over a six-year period…
Larry Luxner
Florida native Larry Luxner, a veteran journalist and photographer, has reported from more than 100 countries in Latin America, Africa, Eastern Europe, the Middle East and Asia for the Miami Herald, the Washington Diplomat, the Journal of Commerce and other news outlets. He lived for many years in San Juan, Puerto Rico, and the Washington, D.C., area. Among other ventures, he launched a monthly newsletter, South America Report, and later published CubaNews for 12 years before relocating to Israel in January 2017 and joining BioNews — first as a copy editor and now as a staff writer. Larry is fluent in Spanish, Portuguese and Hebrew, and enjoys taking long walks around Tel Aviv in his spare time.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Larry Luxner
In recognition of Rare Disease Day 2018, Bionews Services — which publishes this website — will attend and…
A rock-painting contest in Las Vegas. A fashion show in New York. A 7,000-meter race around the Washington Monument that’ll…
David Curtis Glebe, a retired 64-year-old public prosecutor now living in Millsboro, Delaware, knows he’s lucky to be alive. In…
This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into…
The National Organization for Rare Disorders (NORD) says it’s “disappointed and dismayed” after the House of Representatives voted 227-205…
Children’s National Health System no longer treats just kids. Its Rare Disease Institute, launched in April 2017, has partnered with…
More therapies are now available for the 30 million or so people with rare diseases in the U.S. than ever…
#NORDsummit – Despite Criticism, Orphan Drug Act Is Working to Advance Needed Treatments, FDA Says
As Congress begins debate this week to overhaul the U.S. tax code, lawmakers should leave the Orphan Drug Act (ODA)…